Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy. Lanman T, Densmore I, Nagpal S, Recht L, et al. Neurology 2025;105:e213797.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lanman T, Densmore I, Nagpal S, Recht L, et al. Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy. Neurology 2025;105:e213797.
PMID: 40513058